The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The Cambridge, England-based pharmaceutical company said its Kalos and Logos phase 3 trials showed Breztri achieved statistically significant and clinically meaningful improvements in lung function ...